New Zealand allocates $604M to expand drug access for cancer, heart failure, and other conditions.

New Zealand's government has allocated an additional $604 million to Pharmac, the country's pharmaceutical funding agency, significantly boosting medication access. The funding will benefit patients with cancer, chronic heart failure, and ADHD, as well as provide home test kits for abortion effectiveness. About 112 cancer patients will access Lenvatinib, while 18,000 heart failure patients will benefit from new treatments, growing to 33,000 annually by 2029. The investment aims to enhance New Zealand's healthcare system.

November 30, 2024
7 Articles